SUPRAN BRYAN
Known title: EVP, CLO and SecretaryCIK: 0001511797
Associated companies
Transaction History
| ALNY | ▼ Sell | Open Market | 1,758 | $399K | 10/2/2026 | View on chart |
| ALNY | ▲ Buy | Grant | 1,539 | $0 | 3/2/2026 | View on chart |
| ALNY | ▲ Buy | Grant | 13,026 | $0 | 10/1/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Alnylam Q3 Earnings Call Set; Analysts Adjust Targets
Alnylam Pharmaceuticals is preparing to discuss its third-quarter 2026 financial results in an upcoming webcast. Ahead of this event, Citigroup and Wells Fargo maintained their ratings but lowered their price targets to $320 and $253, respectively. These adjustments occur while the stock trades near its 52-week low, reflecting a cautious market stance despite ongoing RNAi commercial momentum.
Alnylam Q3 Earnings Call Set; Analysts Adjust Targets. Alnylam Pharmaceuticals is preparing to discuss its third-quarter 2026 financial results in an upcoming webcast. Ahead of this event, Citigroup and Wells Fargo maintained their ratings but lowered their price targets to $320 and $253, respectively. These adjustments occur while the stock trades near its 52-week low, reflecting a cautious market stance despite ongoing RNAi commercial momentum.